Donepezil Hydrochloride
Product Images NDC 63304-129

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63304-129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ranbaxy Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mglabel (10mglabel)

This is a description of a medication called Donepezil Hydrochloride. It comes in the form of tablets, and the provided code for identification is WoC 62204-120.30.*

FDA Label Image

5mglabel (5mglabel)

This is a description of a medicine called Donepezil Hydrochloride Tablets which has been assigned a registration number of WO 63304-128-30. Other text in the provided data seems to be either numbers or non-relevant characters.*

FDA Label Image

Graph01 (Graph01)

This appears to be a table showing the mean change in ADAS-cog (a cognitive function test) score from baseline after 3, 6, and 12 weeks of treatment with either Donepezil Hydrochloride at 10mg/day, Donepezil Hydrochloride at 5mg/day or a placebo. However, without access to the full data and context, it is difficult to provide a more specific description.*

FDA Label Image

Graph02 (Graph02)

FDA Label Image

Graph03 (Graph03)

This appears to be a table or a chart showing the percentage of patients who have taken either Donepezil Hydrochloride or Placebo and the level of improvement based on the CIBIC-plus rating. The table shows that there were three groups of patients who were administered different treatments: 1) Donepezil Hydrochloride 10mg/day, 2) Donepezil Hydrochloride 5mg/day and 3) Placebo. The rating scale based on patient improvement ranges from Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse and Markedly Worse.*

FDA Label Image

Graph04 (Graph04)

FDA Label Image

Graph05 (Graph05)

This appears to be a graph or chart showing changes in ADAS-cog scores for patients taking different doses of Donopezil Hydrochloride or a placebo. The graph compares a treatment group to a placebo group and shows the cumulative percentage of patients experiencing a certain level of improvement or decline in their scores. Not available.*

FDA Label Image

Graph06 (Graph06)

This is a medical document that seems to present data on patients who were treated with Donepezil Hydrochloride at doses of 5 and 10 mg/day. The medicine's effectiveness was evaluated based on a CIBIC-plus rating, which is a measure of global function and clinical change. The document also includes a chart that displays the percentage of patients who experienced marked, moderate, minimal, or no improvement or a worsening of their condition.*

FDA Label Image

Graph07 (Graph07)

FDA Label Image

Graph08 (Graph08)

This is a description of medication usage. The medication being used is Donepezil Hydrochloride, with a dosage of 10 mg per day. The text also contains information about Placebo, which may be used as an alternative in some cases. The remaining text appears to be a mix of numbers and non-English characters, so it cannot be used to provide further context.*

FDA Label Image

Graph09 (Graph09)

FDA Label Image

Graph10 (Graph10)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.